Your immune system kills roughly 10,000 cancer cells daily through natural killer and dendritic cells. Current checkpoint inhibitors work long-term in only 19% of patients. The speaker argues for spatial biology and immune profiling to identify and strengthen weak points in each patient's immune response.
Another key aspect is the immune system. So I'm going to get into this because this is part of precision targeting our natural killer cells. You know, they're God's gift to our body. Dendritic cells that go out, find cancer cells and kill them. In fact, 10,000 times a day, if you have a healthy immune system, it finds these early mutations and just deletes them, kills them, takes them right out. But in the modern world of again, conventional oncology, they're using immunotherapy like PD1 and PD L1 inhibitors. We've been using these for over a decade, on and off label, and they have their place. But in their long term response rates, you only see about 19% of the cases. In our clinical experience and also according to frontiers and oncology and other groups, it doesn't have the long term response. And you may ask yourself why, because some of these patients may have a PD1 marker, but you don't know to what percentage at the tumor level, meaning they can get immune exhausted and run down. Because it's only one piece of the puzzle. There are other factors to the immune system. And when you do spatial biology, an immune profiling, you can immediately see where the immune system is weak and strengthen it.
